Apyx Medical Corporation (APYX)

Over the past six months, Apyx Medical's stock price has seen significant movement, with the share price at $3.97 as of March 23, 2026, an increase of 187.68% from March 24, 2025. The stock price has fluctuated between a 52-week low of $0.76 and a high of $4.50. Key events impacting the stock include Q3 2025 financial results, a public offering in November 2025, preliminary Q4 and full-year 2025 revenue results, Q4 and full-year 2025 financial results, and FDA submissions and clearances.

Apyx Medical Corporation expects Q3 to be seasonally slower than Q2 and Q4 due to summer vacations.

Apyx Medical Corporation (APYX) is an advanced energy technology company in the Healthcare sector, specifically the Surgical Devices industry. They design, develop, manufacture, and market cosmetic and surgical products, with a core offering of Helium Plasma Platform Technology, including Renuvion® for cosmetic surgery and J-Plasma® for hospital surgery. Major products include Renuvion®, J-Plasma®, AYON Body Contouring System™, and Apyx One Console. Apyx Medical also leverages its expertise through Original Equipment Manufacturing (OEM) agreements.

Apyx Medical Corporation has a global presence, with manufacturing facilities in Clearwater, Florida, and Sofia, Bulgaria. In the United States, products are sold through a direct sales force, while internationally, they are sold through a distributor network. Recent international expansion includes the commercial launch of Renuvion in China in July 2025 and the Apyx One Console in South Korea in Q4 2025. The company has regulatory approvals in Australia, Brazil, Israel, Taiwan, and Thailand.

Apyx Medical's brand reputation has been positively influenced by FDA clearances, product launches and expansion, addressing market needs, and direct-to-consumer marketing. The receipt of 510(k) clearance from the FDA for the AYON Body Contouring System in May 2025 was a significant positive event. The commercial launch of the AYON Body Contouring System in the U.S. in September 2025 has bolstered its standing in the cosmetic surgery market. The company has strategically positioned Renuvion to address the growing patient population experiencing loose skin post-weight loss. Apyx Medical has ramped up its direct-to-consumer marketing program for the Renuvion system.

Apyx Medical Corporation's ownership is distributed among institutional shareholders, individual insiders, and the general public. Institutional shareholders own 49.76% of the company, individual insiders own 21.82%, and retail investors own 28.42%. Major institutional owners include Nantahala Capital Management, LLC, Archon Capital Management LLC, Royce & Associates Lp, Vanguard Group Inc, AIGH Capital Management LLC, Silverberg Bernstein Capital Management LLC, Commonwealth Equity Services, Llc, Horizon Kinetics Asset Management Llc, and BlackRock, Inc. Key individual insiders include Scott Richard Davidson and Stavros G. Vizirgianakis.